Peregrine Ventures
Portfolio Companies
Management Accomplishments
Neovasc Medical Ltd.

Neovasc Medical Ltd. has developed a breakthrough, minimally invasive treatment for Ischemic Heart Disease (IHD) patients, who are not treatable by existing medical procedures. IHD is caused by limited inflow of blood in the coronary arteries, often caused by atherosclerosis, and includes well known and highly common disorders such as angina pectoris (chest pain), diabetic (small vessel) heart disease, and congestive heart failure (CHF).

Neovasc has developed a “negative” stent-like device called the Reducer™, which is a specialized stent for the treatment of refractory angina. Implanted in the coronary sinus, the Reducer’s hourglass shape restricts the venous outflow from the coronary sinus, slightly elevating pressure in the coronary arteries. It is believed that this elevated back-pressure in the coronary arteries forces oxygenated blood deeper within the heart muscle, resulting in relief of angina symptoms.

Simple yet innovative in concept and design, Reducer has the potential to revolutionize treatment for refractory angina, which currently has no effective cure. An initial human trial of 15 patients showed compelling results for the Reducer. The trial’s results were published in the May 2007 edition of Journal of the American College of Cardiology. Specifically, data from the trial showed:

  • No device-related adverse events or complications
  • Significant relief of refractory angina symptoms in 12 of 14 subjects

Activities are currently underway to complete development of the Reducer technology and to obtain required regulatory approvals in the US, Europe and other world markets.

Reducer is in a pre-commercial stage and is not available for sale.

On July 1, 2008, Medical Ventures Corp., a Canadian public company specializing in vascular and surgical devices, merged with Neovasc Medical Ltd. and B-Balloon Ltd., two peregrine portfolio companies, and formed Neovasc, Inc., which shall be focused on the development of product for the heart & vascular disease market.

This transaction brought together each company’s strong intellectual property and outstanding product development capabilities with the management and infrastructure of an established medical device company.

« Back

6 Yoni Netanyahu Street
Or Yehuda 60376, Israel

Israel: +972-3-6346716
Israel: +972-3-6346717
Contact: Mr. Eyal Sandach
Stage: Acquired
© Peregrine Ventures  |  Terms & Conditions  |  Privacy Policy Back to Top